Clinical Trials29 June 2026· 11 min read
UK sets pathway for in vivo CRISPR gene editing trials
The UK is advancing in vivo CRISPR gene editing beyond ex vivo models. Explore regulatory signals, lipid nanoparticle delivery, and NHS reimbursement challenges.
By Dr. Eleanor Vance, Regulatory Affairs Editor
Clinical Trials17 June 2026· 10 min read
Microbiome on a chip could cut drug trial failures
Microbiome on chip systems could revolutionise drug discovery by providing human-relevant gut testing, potentially reducing the 90% clinical trial failure rate.
By Tom Okafor, Clinical Trials Correspondent
Research15 June 2026· 12 min read
Liquid biopsies could reshape NHS cancer screening in 2026
Liquid biopsies NHS pilot tests multi-cancer early detection to reshape screening pathways and achieve 75% Stage I-II cancer diagnosis by 2028.
By Megan Liu, Digital Health Reporter
Research10 June 2026· 9 min read
Amyloid therapies reach limits as multi-target strategies advance
The approval of amyloid-targeting monoclonal antibodies by the MHRA marked a clear regulatory and scientific milestone in Alzheimer’s disease treatment. These agents demonstrated that disease-modifyin
By Dr. Eleanor Vance, Regulatory Affairs Editor
Clinical Trials10 June 2026· 14 min read
UK Clinical Trial Reforms 2026: Accelerating Approvals
The UK clinical trial regulation package, taking effect on 28 April 2026, is designed to deliver faster, more predictable approvals while preserving participant protections. Its headline operational c
By Tom Okafor, Clinical Trials Correspondent
Research7 May 2026· 13 min read
Microgravity helps find new antimicrobials for superbugs
Microgravity is increasingly recognised as a valuable tool for antimicrobial discovery due to its impact on microbial interactions, competition, and adaptation. Evidence from the International Space S
By Dr. Eleanor Vance, Regulatory Affairs Editor
Cancer4 March 2026· 8 min read
NHS expands abiraterone access for high-risk prostate
NHS England has widened abiraterone acetate access for adults with high-risk non-metastatic prostate cancer, with treatment expected to reach eligible patients within weeks. The change matters because
By Tom Okafor, Clinical Trials Correspondent
Pharmaceutical2 February 2026· 9 min read
Pharmacogenomics Shapes Safer NHS Prescribing in 2026
The NHS has entered a decisive phase in the use of pharmacogenomics, moving from targeted pilots to routine medicines optimisation informed by genetic data. By 2026, evidence from national implementat
By Priya Raghavan, Biotech & Markets Analyst
Research5 January 2026· 10 min read
Personalised medicines: the new frontier, the rise of CRISPR-based therapies in oncology
The first regulatory approvals for a CRISPR-based medicine in the UK and EU marked a turning point for genomic medicine and set expectations for oncology. In 2023, the MHRA licensed exagamglogene auto
By Dr. Eleanor Vance, Regulatory Affairs Editor
Clinical Trials2 January 2026· 12 min read
AI speeds drug discovery as pharma takes risks in 2026
AI drug discovery shifts from promise to operational impact as pharma adopts risk-on posture amid tightening patent cliff timeline in 2026.
By Tom Okafor, Clinical Trials Correspondent
Clinical Trials12 December 2025· 21 min read
UK clinical trials pay surges in 2026
The United Kingdom enters 2026 as one of the most active environments in the world for high-paying clinical trials, particularly early phase studies involving healthy volunteers. Regulatory reforms, f
By Tom Okafor, Clinical Trials Correspondent
Research2 December 2025· 4 min read
The Role of Cathepsin B (CTSB) in Immune Response Studies
Cathepsin B (CTSB) is a lysosomal cysteine protease that plays a key role in protein turnover, antigen processing, and immune regulation. It is widely expressed across mammalian tissues. Recent resear
By Dr. Eleanor Vance, Regulatory Affairs Editor